ImmunityBio, Inc. (NasdaqGS: IBRX)
Health Care · Biotechnology · US
$7.58
-2.82% today · +236.9% 1Y
ImmunityBio, Inc. (NasdaqGS: IBRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.03B and employs 688 people.
Over the last twelve months the share price has gained 236.9%, trading between 1.95 and 12.43.
Tweenvest scores ImmunityBio, Inc. across four factors: quality 11/100, value 74/100. Its strongest factor is value.
IBRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.03B
- Revenue (TTM)
- $165.79M
- P/E
- —
- EPS
- -0.99
- Dividend yield
- —
- Beta (5Y)
- 0.13
- 52-week high
- $12.43
- 52-week low
- $1.95
- Avg volume (3M)
- —
- Shares outstanding
- 1.06B
- Employees
- 688
- Next earnings
- —
About ImmunityBio, Inc.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
- ISIN
- US45256X1037
- Listed since
- Jul 28, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.83 | +2.12% |
Figures last refreshed Aug 18, 2026.